Drug Trial Radar · NCT01678872
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Aug 2012
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Oxford BioMedicaIndustry
- Sponsor type
- Industry
- First posted
- Sep 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.
Conditions
- Age-Related Macular Degeneration
Interventions
RetinoStatDrug
Long Term Follow up of patients who received RetinoStat in a previous study
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of adverse eventsTime frame: 14 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Iowa Hospitals & Clinics
Iowa City, Iowa
John Hopkins University Hospital
Baltimore, Maryland
Oregon Health & Science University
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.